# Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis

> **NCT04209205** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 381 (actual)

## Conditions studied

- Psoriatic Arthritis

## Interventions

- **DRUG:** AIN457 6 mg/kg i.v.
- **DRUG:** Placebo
- **DRUG:** AIN457 3 mg/kg

## Key facts

- **NCT ID:** NCT04209205
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-29
- **Primary completion:** 2022-05-17
- **Final completion:** 2022-05-17
- **Target enrollment:** 381 (ACTUAL)
- **Last updated:** 2025-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04209205

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04209205, "Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04209205. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*